文献速递血液净化与透析肾移植

澳大利亚与新西兰儿童肾脏替代治疗流行病学及结局

Epidemiology and Outcomes of Children with Kidney Failure Receiving Kidney Replacement Therapy in Australia and New Zealand.
PubMed 文献 · Kidney Int Rep · 2023-07-22

该研究基于澳大利亚与新西兰透析和移植登记系统,纳入2000至2020年启动肾脏替代治疗的1058例18岁以下儿童,分析患者生存率、技术生存率及移植物生存率。结果显示腹膜透析是最常见起始模式,患者生存率与技术生存率在两个十年间无显著差异,但2011-2020年移植物生存率显著高于2000-2010年。

要点

  • 儿童起始肾脏替代治疗模式以腹膜透析最常见(48%),其次为血液透析(34%)和肾移植(18%)。
  • 2011-2020年与2000-2010年5年患者生存率无显著差异(96.9% vs 94.5%,P=0.79)。
  • 2011-2020年5年移植物生存率显著高于2000-2010年(88.4% vs 84.3%,P<0.001)。

核心结论

  • 腹膜透析是澳大利亚与新西兰儿童最常用的起始肾脏替代治疗模式,患者生存率、技术生存率及移植物生存率均优异,且移植物生存率在过去20年间有所改善。

研究设计与样本

  • 基于澳大利亚与新西兰透析和移植登记系统的队列研究,纳入2000年1月1日至2020年12月31日启动肾脏替代治疗的1058例18岁以下儿童,中位随访12.3年,采用Cox回归分析患者生存率、技术生存率及移植物生存率。

主要发现

  • 1058例儿童中位年龄11岁(IQR 5-15),女性占41%,白人占66%。
  • 首次肾脏替代治疗模式为腹膜透析(48%)、血液透析(34%)和肾移植(18%)。
  • 先发肾移植发生率在白人儿童中最高(80.4%),在原住民人群中最低(3.2%)。
  • 2011-2020年5年患者生存率为96.9%(95%CI 93.8-98.4),2000-2010年为94.5%(95%CI 90.4-96.8),两组无显著差异(P=0.79)。
  • 2011-2020年5年删失死亡的技术生存率为51.2%(95%CI 39.1-62),2000-2010年为48.8%(95%CI 40.5-56.6),两组无显著差异(P=0.27)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The incidence and outcomes of kidney replacement therapy (KRT) have been well-studied in adults, but much less so in children. This study aimed to investigate the epidemiology and outcomes of KRT in children in Australia and New Zealand from 2000 to 2020. METHODS: Children aged <18 years initiating KRT in Australia and New Zealand between January 1, 2000 and December 31, 2020 and reported to the Australia and New Zealand Dialysis and Transplant Registry were included. Patient survival, technique-survival, and graft survival were analyzed by Cox regression analyses. RESULTS: Overall, 1058 children (median [interquartile range (IQR)] age 11 [5-15] years, 41% female, 66% White) were followed-up with for a median period of 12.3 years. First KRT modalities were peritoneal dialysis (PD; 48%), hemodialysis (HD; 34%), and kidney transplantation (KT; 18%). Pre-emptive KT incidence was highest in Caucasian children (80.4%) and lowest in the Indigenous population (3.2%). There was no difference in 5-year patient survival rates between 2011 and 2020 (96.9%, 95% confidence interval [CI] 93.8-98.4) and the preceding decade, 2000-2010 (94.5%, 95% CI 90.4-96.8) (P = 0.79). There was no difference in 5-year death-censored technique survival between 2011 and 2020 (51.2%, 95% CI 39.1-62) and 2000-2010 (48.8%, 95% CI 40.5-56.6) (P = 0.27). However, 5-year derath-censored graft survival was significantly higher in 2011-2020 (88.4%, 95% CI 84.6-91.4) than in 2000-2010 (84.3%, 95% CI 80.4-87.5) (P < 0.001). CONCLUSIONS: PD is the most commonly prescribed KRT modality for children in Australia and New Zealand. Patient-survival, technique-survival, and graft survival rates are excellent and graft survival has improved over the last 2 decades.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ambarsari CG, Cho Y, Milanzi E, et al. Epidemiology and Outcomes of Children with Kidney Failure Receiving Kidney Replacement Therapy in Australia and New Zealand. Kidney Int Rep. 2023. PMID: 37850025. doi:10.1016/j.ekir.2023.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。